Exact Mass: 903.4801

Exact Mass Matches: 903.4801

Found 69 metabolites which its exact mass value is equals to given mass value 903.4801, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dol-P-GlcNAc-Glc-2,3-diNAcA

Dol-P-GlcNAc-Glc-2,3-diNAcA

C43H74N3O15P (903.4857)


   

Des-arg(9)-bradykinin

2-[(1-{2-[2-(2-{[1-(1-{2-amino-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidine-2-carbonyl)pyrrolidin-2-yl]formamido}acetamido)-3-phenylpropanamido]-3-hydroxypropanoyl}pyrrolidin-2-yl)formamido]-3-phenylpropanoic acid

C44H61N11O10 (903.4603)


   

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-(phosphonooxy)propan-2-yl]oxy}-3-oxopropyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C48H74NO11PS (903.472)


PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-(phosphonooxy)propoxy]-3-oxopropyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C48H74NO11PS (903.472)


PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(16:1(9Z)/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-({[(2S)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)-3-[(9Z)-hexadec-9-enoyloxy]propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C45H78NO13PS (903.4931)


PG(16:1(9Z)/LTE4) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(16:1(9Z)/LTE4), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(LTE4/16:1(9Z))

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-3-({[(2S)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)-2-[(9Z)-hexadec-9-enoyloxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C45H78NO13PS (903.4931)


PG(LTE4/16:1(9Z)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(LTE4/16:1(9Z)), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

(2S)-2-amino-3-({[(2R)-3-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(4Z,7Z,10Z,13Z,16Z))

(2S)-2-amino-3-({[(2R)-2-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(4Z,7Z,10Z,13Z,16Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

(2S)-2-amino-3-({[(2R)-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(7Z,10Z,13Z,16Z,19Z))

(2S)-2-amino-3-({[(2R)-2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGE2)

(2S)-2-amino-3-({[(2R)-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGE2) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGE2), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(PGE2/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(2S)-2-amino-3-({[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(PGE2/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(PGE2/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGD2)

(2S)-2-amino-3-({[(2R)-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGD2) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGD2), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(PGD2/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(2S)-2-amino-3-({[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(PGD2/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(PGD2/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

(2S)-2-amino-3-({[(2R)-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(2S)-2-amino-3-({[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C48H74NO13P (903.4898)


PS(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   
   

[des-Arg9]bradykinin

[des-Arg9]bradykinin

C44H61N11O10 (903.4603)


   
   
   

Dehydrodolastatin 13

Dehydrodolastatin 13

C46H61N7O12 (903.4378)


   

cyclo-[DHMHDA-L-Ser-D-Ala-D-Asp-L-Ala-D-Ser-D-Ser-D-allo-Thr]|phaeofungin

cyclo-[DHMHDA-L-Ser-D-Ala-D-Asp-L-Ala-D-Ser-D-Ser-D-allo-Thr]|phaeofungin

C40H69N7O16 (903.4801)


   

Phakellistatin 10

Phakellistatin 10

C47H69N9O9 (903.5218)


   

(des-arg9)-Bradykinin

(Des-Arg9)-Bradykinin acetate salt

C44H61N11O10 (903.4603)


   

Bradykinin Fragment 2-9

Bradykinin Fragment 2-9

C44H61N11O10 (903.4603)


Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.

   

Pyr-Asp-Pro-Phe-Leu-Arg-Phe-NH2

Pyr-Asp-Pro-Phe-Leu-Arg-Phe-NH2

C44H61N11O10 (903.4603)


Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa is a FMRF-like peptide from visceral and somatic muscles of the snail Helix aspersa. FMRF (Phe-Met-Arg-Phe) is a neuropeptide peptide consisting of 4 amino acid residues[1].

   

Dihydrogeranylgeranyl bacteriochlorophyllide b

Dihydrogeranylgeranyl bacteriochlorophyllide b

C55H67MgN4O6- (903.4911)


   

magnesium;(11R,12R,21S,22S)-16-acetyl-11-ethyl-3-methoxycarbonyl-12,17,21,26-tetramethyl-22-[3-oxo-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoxy]propyl]-23,25-diaza-7,24-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1(23),2(6),3,5(26),8,10(25),13,15,17,19-decaen-4-olate

magnesium;(11R,12R,21S,22S)-16-acetyl-11-ethyl-3-methoxycarbonyl-12,17,21,26-tetramethyl-22-[3-oxo-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoxy]propyl]-23,25-diaza-7,24-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1(23),2(6),3,5(26),8,10(25),13,15,17,19-decaen-4-olate

C55H67MgN4O6- (903.4911)


   
   
   

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/LTE4)

C48H74NO11PS (903.472)


   

PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PA(LTE4/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C48H74NO11PS (903.472)


   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGE2)

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGE2)

C48H74NO13P (903.4898)


   

PS(PGE2/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PS(PGE2/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C48H74NO13P (903.4898)


   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGD2)

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/PGD2)

C48H74NO13P (903.4898)


   

PS(PGD2/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PS(PGD2/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C48H74NO13P (903.4898)


   

PS(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PS(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C48H74NO13P (903.4898)


   

PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(4Z,7Z,10Z,13Z,16Z))

PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(4Z,7Z,10Z,13Z,16Z))

C48H74NO13P (903.4898)


   

PS(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PS(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C48H74NO13P (903.4898)


   

PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(7Z,10Z,13Z,16Z,19Z))

PS(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:5(7Z,10Z,13Z,16Z,19Z))

C48H74NO13P (903.4898)


   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C48H74NO13P (903.4898)


   

PS(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PS(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C48H74NO13P (903.4898)


   

[Des-Arg9]-BRADYKININ

(Des-Arg9)-Bradykinin acetate salt

C44H61N11O10 (903.4603)


   

(2S,3S,4R,5R,6R)-4,5-diacetamido-6-[(2R,3S,4R,5R,6R)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-[hydroxy-[(6Z,10E,14E)-3,7,11,15,19-pentamethylicosa-6,10,14-trienoxy]phosphoryl]oxyoxan-4-yl]oxy-3-hydroxyoxane-2-carboxylic acid

(2S,3S,4R,5R,6R)-4,5-diacetamido-6-[(2R,3S,4R,5R,6R)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-[hydroxy-[(6Z,10E,14E)-3,7,11,15,19-pentamethylicosa-6,10,14-trienoxy]phosphoryl]oxyoxan-4-yl]oxy-3-hydroxyoxane-2-carboxylic acid

C43H74N3O15P (903.4857)


   

cyclo[D-Leu-D-Pro-Trp-Val-Pro-D-Leu-Thr-Pro]

cyclo[D-Leu-D-Pro-Trp-Val-Pro-D-Leu-Thr-Pro]

C47H69N9O9 (903.5218)


   

H-Arg-Pro-Pro-Gly-Phe-Ser-DL-Pro-Phe-OH

H-Arg-Pro-Pro-Gly-Phe-Ser-DL-Pro-Phe-OH

C44H61N11O10 (903.4603)


   

(6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

C44H73NO18 (903.4827)


   

(4Z,7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

C44H73NO18 (903.4827)


   

(3Z,6Z,9Z,12Z,15Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]octadeca-3,6,9,12,15-pentaenamide

C44H73NO18 (903.4827)


   

H-Arg-Pro-Pro-Gly-D-Phe-Ser-DL-Pro-Phe-OH

H-Arg-Pro-Pro-Gly-D-Phe-Ser-DL-Pro-Phe-OH

C44H61N11O10 (903.4603)


   

H-Pro-Pro-Gly-D-Phe-Ser-D-Pro-D-Phe-D-Arg-OH

H-Pro-Pro-Gly-D-Phe-Ser-D-Pro-D-Phe-D-Arg-OH

C44H61N11O10 (903.4603)


   
   
   
   

Hex3Cer 26:5;O2

Hex3Cer 26:5;O2

C44H73NO18 (903.4827)


   

Acetyl-PHF6 amide (TFA)

Acetyl-PHF6 amide (TFA)

C40H64F3N9O11 (903.4677)


Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide.

   

(2s)-2-{[(2r)-2-{[(2s)-2-[(2-{[2-({[(2s)-1-[(2r)-2-{[(2s)-2-{[(2s)-2,6-diamino-1-hydroxyhexylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-3-sulfanylpropanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-4-(c-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxy-3-sulfanylpropylidene]amino}-3-methylbutanoic acid

(2s)-2-{[(2r)-2-{[(2s)-2-[(2-{[2-({[(2s)-1-[(2r)-2-{[(2s)-2-{[(2s)-2,6-diamino-1-hydroxyhexylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-3-sulfanylpropanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-4-(c-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxy-3-sulfanylpropylidene]amino}-3-methylbutanoic acid

C37H65N11O11S2 (903.4306)


   

5,14,17,26,29-pentahydroxy-12-(1-hydroxyethyl)-27-(1h-indol-3-ylmethyl)-24-isopropyl-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

5,14,17,26,29-pentahydroxy-12-(1-hydroxyethyl)-27-(1h-indol-3-ylmethyl)-24-isopropyl-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

C47H69N9O9 (903.5218)


   

(2r)-2-({3-[(2-{[(2r)-2-{[(2s)-2-{[(2r)-2-[(3-amino-1-hydroxy-4-methyl-7-phenylhept-6-en-1-ylidene)amino]-1,3-dihydroxypropylidene]amino}-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-2-methylpropylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

(2r)-2-({3-[(2-{[(2r)-2-{[(2s)-2-{[(2r)-2-[(3-amino-1-hydroxy-4-methyl-7-phenylhept-6-en-1-ylidene)amino]-1,3-dihydroxypropylidene]amino}-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-2-methylpropylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

C46H61N7O12 (903.4378)


   

(3r,6s,12s,15r,18s,24s,27s,30r)-5,14,17,26,29-pentahydroxy-12-[(1r)-1-hydroxyethyl]-27-(1h-indol-3-ylmethyl)-24-isopropyl-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

(3r,6s,12s,15r,18s,24s,27s,30r)-5,14,17,26,29-pentahydroxy-12-[(1r)-1-hydroxyethyl]-27-(1h-indol-3-ylmethyl)-24-isopropyl-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

C47H69N9O9 (903.5218)


   

(12e,19z,21e)-24-[(3z)-5-[2-(2,3-dimethyloxiran-2-yl)-1,3-thiazol-4-yl]-2-hydroxy-4-methylpent-3-en-2-yl]-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl 3-hydroxy-2-methylbutanoate

(12e,19z,21e)-24-[(3z)-5-[2-(2,3-dimethyloxiran-2-yl)-1,3-thiazol-4-yl]-2-hydroxy-4-methylpent-3-en-2-yl]-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl 3-hydroxy-2-methylbutanoate

C49H77NO12S (903.5166)


   

[(3r,6r,9r,12s,15r,18r,21s)-5,8,11,14,17,20,23-heptahydroxy-3-[(1r)-1-hydroxyethyl]-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

[(3r,6r,9r,12s,15r,18r,21s)-5,8,11,14,17,20,23-heptahydroxy-3-[(1r)-1-hydroxyethyl]-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

C40H69N7O16 (903.4801)


   

(3s,6r,8s,9r,11r,12z,15s,16s,17s,18r,19e,21e,23s,24r)-24-[(2r,3z)-5-{2-[(2s,3r)-2,3-dimethyloxiran-2-yl]-1,3-thiazol-4-yl}-2-hydroxy-4-methylpent-3-en-2-yl]-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl (2r,3s)-3-hydroxy-2-methylbutanoate

(3s,6r,8s,9r,11r,12z,15s,16s,17s,18r,19e,21e,23s,24r)-24-[(2r,3z)-5-{2-[(2s,3r)-2,3-dimethyloxiran-2-yl]-1,3-thiazol-4-yl}-2-hydroxy-4-methylpent-3-en-2-yl]-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl (2r,3s)-3-hydroxy-2-methylbutanoate

C49H77NO12S (903.5166)


   

(3s,6s,12s,15s,18s,24s,27s,30s)-5,14,17,26,29-pentahydroxy-12-[(1r)-1-hydroxyethyl]-27-(1h-indol-3-ylmethyl)-24-isopropyl-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

(3s,6s,12s,15s,18s,24s,27s,30s)-5,14,17,26,29-pentahydroxy-12-[(1r)-1-hydroxyethyl]-27-(1h-indol-3-ylmethyl)-24-isopropyl-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

C47H69N9O9 (903.5218)


   

3-methoxy-n-(1-{methyl[2-methyl-1-({2-methyl-1-[methyl({2-methyl-1-[methyl({1-[methyl(1,3-thiazol-2-ylmethyl)carbamoyl]-2-phenylethyl})carbamoyl]butyl})carbamoyl]propyl}-c-hydroxycarbonimidoyl)propyl]carbamoyl}-2-phenylethyl)hexanimidic acid

3-methoxy-n-(1-{methyl[2-methyl-1-({2-methyl-1-[methyl({2-methyl-1-[methyl({1-[methyl(1,3-thiazol-2-ylmethyl)carbamoyl]-2-phenylethyl})carbamoyl]butyl})carbamoyl]propyl}-c-hydroxycarbonimidoyl)propyl]carbamoyl}-2-phenylethyl)hexanimidic acid

C49H73N7O7S (903.5292)


   

(3r)-3-methoxy-n-[(1s)-1-{methyl[(1r)-2-methyl-1-{[(1s)-2-methyl-1-{methyl[(1s,2s)-2-methyl-1-{methyl[(1s)-1-[methyl(1,3-thiazol-2-ylmethyl)carbamoyl]-2-phenylethyl]carbamoyl}butyl]carbamoyl}propyl]-c-hydroxycarbonimidoyl}propyl]carbamoyl}-2-phenylethyl]hexanimidic acid

(3r)-3-methoxy-n-[(1s)-1-{methyl[(1r)-2-methyl-1-{[(1s)-2-methyl-1-{methyl[(1s,2s)-2-methyl-1-{methyl[(1s)-1-[methyl(1,3-thiazol-2-ylmethyl)carbamoyl]-2-phenylethyl]carbamoyl}butyl]carbamoyl}propyl]-c-hydroxycarbonimidoyl}propyl]carbamoyl}-2-phenylethyl]hexanimidic acid

C49H73N7O7S (903.5292)


   

[5,8,11,14,17,20,23-heptahydroxy-3-(1-hydroxyethyl)-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

[5,8,11,14,17,20,23-heptahydroxy-3-(1-hydroxyethyl)-6,9,21-tris(hydroxymethyl)-25-(2-hydroxytetradecan-2-yl)-12,18-dimethyl-2-oxo-1-oxa-4,7,10,13,16,19,22-heptaazacyclopentacosa-4,7,10,13,16,19,22-heptaen-15-yl]acetic acid

C40H69N7O16 (903.4801)


   

24-{5-[2-(2,3-dimethyloxiran-2-yl)-1,3-thiazol-4-yl]-2-hydroxy-4-methylpent-3-en-2-yl}-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl 3-hydroxy-2-methylbutanoate

24-{5-[2-(2,3-dimethyloxiran-2-yl)-1,3-thiazol-4-yl]-2-hydroxy-4-methylpent-3-en-2-yl}-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl 3-hydroxy-2-methylbutanoate

C49H77NO12S (903.5166)


   

(12z,19e,21e)-24-[(3z)-5-[2-(2,3-dimethyloxiran-2-yl)-1,3-thiazol-4-yl]-2-hydroxy-4-methylpent-3-en-2-yl]-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl 3-hydroxy-2-methylbutanoate

(12z,19e,21e)-24-[(3z)-5-[2-(2,3-dimethyloxiran-2-yl)-1,3-thiazol-4-yl]-2-hydroxy-4-methylpent-3-en-2-yl]-8,16,17-trihydroxy-18-methoxy-3,6,9,11,15,19,23-heptamethyl-2,10-dioxo-1-oxacyclotetracosa-12,19,21-trien-3-yl 3-hydroxy-2-methylbutanoate

C49H77NO12S (903.5166)